公开(公告)号：WO2012045194A1

公开(公告)日：2012-04-12

申请号：PCT/CN2010/001577

申请日：2010-10-09

Applicant: ABBOTT LABORATORIES ,  ABBOTT LABORATORIES TRADING(SHANGHAI) COMPANY, LTD. ,  VAN CAMP, Jennifer ,  PATEL, Jyoti, R. ,  SWANN, Steven

Inventor： VAN CAMP, Jennifer ,  PATEL, Jyoti, R. ,  SWANN, Steven

IPC: C07D243/38 ,  C07D401/04 ,  A61K31/5513 ,  A61K31/4427 ,  A61P35/04

CPC classification number: C07D243/38 ,  C07D401/04

Abstract: Disclosed are compounds which inhibit the activity of focal adhesion kinase, compositions containing the compounds, and methods of treating diseases during which focal adhesion kinase is expressed.

Abstract translation: 公开了抑制粘着斑激酶活性的化合物，含有该化合物的组合物，以及治疗粘着斑激酶表达的疾病的方法。

公开(公告)号：WO2002070507A2

公开(公告)日：2002-09-12

申请号：PCT/US2002/004541

申请日：2002-01-16

Applicant: ABBOTT LABORATORIES

Inventor： KYM, Philip, R. ,  LANE, Benjamin, C. ,  PRATT, John, K. ,  VON GELDERN, Tom ,  WINN, Martin ,  PATEL, Jyoti, R. ,  ARENDSEN, David, L. ,  AKRITOPOULOU-ZANZE, Irini ,  ASHWORTH, Kimba, L. ,  HARTANDI, Kresna ,  BRENNEMAN, Jehrod

IPC: C07D311/80

CPC classification number: C07D407/04 ,  C07D311/80 ,  C07D409/04

Abstract: Compounds of formula (I) are useful for treating type (II) diabetes, obesity, hyperglycemia, inadequate glucose clearance, hyperinsulinemia, hypertriglyceridemia, and high-circulating glucocorticoid levels, preparations of the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Abstract translation: 式（I）化合物可用于治疗II型糖尿病，肥胖症，高血糖症，葡萄糖清除不足，高胰岛素血症，高甘油三酯血症和高循环糖皮质激素水平，所述化合物的制剂，含有 化合物和使用这些化合物的治疗方法。

公开(公告)号：WO2005108368A1

公开(公告)日：2005-11-17

申请号：PCT/US2005/015304

申请日：2005-04-29

Applicant: ABBOTT LABORATORIES ,  LINK, James, T. ,  PLIUSHCHEV, Marina, A. ,  ROHDE, Jeffrey, J. ,  WODKA, Dariusz ,  PATEL, Jyoti, R. ,  SHUAI, Qi

Inventor： LINK, James, T. ,  PLIUSHCHEV, Marina, A. ,  ROHDE, Jeffrey, J. ,  WODKA, Dariusz ,  PATEL, Jyoti, R. ,  SHUAI, Qi

IPC: C07D213/06

CPC classification number: C07D213/06 ,  C07C237/04 ,  C07C237/24 ,  C07C2601/02 ,  C07C2603/74 ,  C07D207/02 ,  C07D209/08 ,  C07D213/24 ,  C07D213/72 ,  C07D213/74 ,  C07D213/85 ,  C07D223/16 ,  C07D253/06 ,  C07D257/04 ,  C07D277/64 ,  C07D295/15 ,  C07D295/185 ,  C07D471/08 ,  C07D491/04

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征以及其它疾病和病症的用途 由过度的糖皮质激素作用介导。

公开(公告)号：WO2009026422A3

公开(公告)日：2009-02-26

申请号：PCT/US2008/073830

申请日：2008-08-21

Applicant: ABBOTT LABORATORIES ,  BITNER, R., Scott ,  BROWMAN, Kaitlin, E ,  BRUNE, Michael, E ,  CHEN, Yixian ,  DINGES, Jurgen ,  DRESCHER, Karla ,  JACOBSON, Peer ,  JAE, Hwan-soo ,  KURUKULASURIYA, Ravi ,  LINK, James, T. ,  MADAR, David, J. ,  PATEL, Jyoti, R. ,  PLIUSHCHEV, Marina, A. ,  ROHDE, Jeffrey, J. ,  RUETER, Lynne, E. ,  SHUAI, Qi ,  SORENSEN, Bryan, K. ,  WANG, Jiahong ,  WICKE, Karsten, M. ,  WINN, Martin ,  WODKA, Dariusz ,  YEH, Vince ,  YONG, Hong

Inventor： BITNER, R., Scott ,  BROWMAN, Kaitlin, E ,  BRUNE, Michael, E ,  CHEN, Yixian ,  DINGES, Jurgen ,  DRESCHER, Karla ,  JACOBSON, Peer ,  JAE, Hwan-soo ,  KURUKULASURIYA, Ravi ,  LINK, James, T. ,  MADAR, David, J. ,  PATEL, Jyoti, R. ,  PLIUSHCHEV, Marina, A. ,  ROHDE, Jeffrey, J. ,  RUETER, Lynne, E. ,  SHUAI, Qi ,  SORENSEN, Bryan, K. ,  WANG, Jiahong ,  WICKE, Karsten, M. ,  WINN, Martin ,  WODKA, Dariusz ,  YEH, Vince ,  YONG, Hong

IPC: A61K31/495 ,  A61K31/445 ,  C07C233/23 ,  C07D471/02

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.

公开(公告)号：WO2006074244A2

公开(公告)日：2006-07-13

申请号：PCT/US2006/000210

申请日：2006-01-05

Applicant: ABBOTT LABORATORIES ,  PATEL, Jyoti, R. ,  SHUAI, Qi ,  LINK, James, T. ,  ROHDE, Jeffrey, J. ,  DINGES, Jurgen ,  SORENSEN, Bryan, K. ,  WINN, Martin ,  YONG, Hong ,  YEH, Vince, S.

Inventor： PATEL, Jyoti, R. ,  SHUAI, Qi ,  LINK, James, T. ,  ROHDE, Jeffrey, J. ,  DINGES, Jurgen ,  SORENSEN, Bryan, K. ,  WINN, Martin ,  YONG, Hong ,  YEH, Vince, S.

IPC: C07C235/14 ,  C07C317/16 ,  C07C323/41 ,  C07D257/04 ,  C07D233/54 ,  C07D261/08 ,  C07D213/64 ,  C07D207/48 ,  A61K31/4402 ,  A61P3/10

CPC classification number: C07C233/23 ,  C07C235/14 ,  C07C237/24 ,  C07C255/31 ,  C07C255/47 ,  C07C259/16 ,  C07C311/08 ,  C07C311/29 ,  C07C311/46 ,  C07C311/51 ,  C07C317/22 ,  C07C317/30 ,  C07C317/44 ,  C07C323/41 ,  C07C323/60 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/74 ,  C07D207/48 ,  C07D213/64 ,  C07D233/64 ,  C07D257/04 ,  C07D261/08

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。

公开(公告)号：WO2006074330A2

公开(公告)日：2006-07-13

申请号：PCT/US2006/000402

申请日：2006-01-05

Applicant: ABBOTT LABORATORIES ,  ROHDE, Jeffrey, J. ,  SHUAI, Qi ,  LINK, James, T. ,  PATEL, Jyoti, R. ,  DINGES, Jurgen ,  SORENSEN, Bryan, K. ,  YONG, Hong

Inventor： ROHDE, Jeffrey, J. ,  SHUAI, Qi ,  LINK, James, T. ,  PATEL, Jyoti, R. ,  DINGES, Jurgen ,  SORENSEN, Bryan, K. ,  YONG, Hong

IPC: C07C233/63 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24 ,  A61K31/165 ,  A61K31/4409 ,  A61K31/381 ,  A61K31/415 ,  A61K31/42 ,  A61P3/04 ,  A61P3/10

CPC classification number: C07D207/277 ,  C07C233/11 ,  C07C233/52 ,  C07C233/58 ,  C07C233/63 ,  C07C237/24 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/74 ,  C07D211/78 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶的抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。

公开(公告)号：WO2002064550A1

公开(公告)日：2002-08-22

申请号：PCT/US2002/004501

申请日：2002-02-12

Applicant: ABBOTT LABORATORIES

Inventor： LINK, James, T. ,  SORENSEN, Bryan, K. ,  PATEL, Jyoti, R. ,  ARENDSEN, David, L. ,  LI, Gaoquan

IPC: C07C307/04

CPC classification number: C07D295/088 ,  C07C307/10 ,  C07C311/08 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/18

Abstract: Compounds of formula (I) (I), or pharmaceutically acceptable salts thereof are novel glucocorticoid receptor modulators and are useful for treating type II diabetes in a mammal.

Abstract translation: 式（I）（I）化合物或其药学上可接受的盐是新颖的糖皮质激素受体调节剂，并且可用于治疗哺乳动物中的II型糖尿病。

公开(公告)号：EP1272456B1

公开(公告)日：2004-10-27

申请号：EP01925029.9

申请日：2001-04-13

Applicant: Abbott Laboratories

Inventor： CRAIG, Richard, A. ,  KAWAI, Megumi ,  LYNCH, Linda, M. ,  PATEL, Jyoti, R. ,  SHEPPARD, George, S. ,  WANG, Jieyi ,  YANG, Fan ,  BA-MAUNG, Nwe, Y.

IPC: C07C243/28 ,  C07C239/20 ,  C07C321/14 ,  C07D215/46 ,  C07D213/75 ,  C07D237/20 ,  A61K31/165 ,  A61K31/175 ,  A61K31/18 ,  A61K31/435 ,  A61K31/50

CPC classification number: C07D207/416 ,  C07B2200/07 ,  C07C243/34 ,  C07C243/38 ,  C07C251/86 ,  C07C255/42 ,  C07C255/66 ,  C07C259/06 ,  C07C281/02 ,  C07C281/06 ,  C07C311/38 ,  C07C323/41 ,  C07C323/60 ,  C07C323/62 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/18 ,  C07D207/50 ,  C07D209/20 ,  C07D211/12 ,  C07D211/62 ,  C07D213/38 ,  C07D213/54 ,  C07D213/77 ,  C07D213/86 ,  C07D215/42 ,  C07D231/14 ,  C07D231/38 ,  C07D237/14 ,  C07D237/20 ,  C07D237/24 ,  C07D239/42 ,  C07D241/44 ,  C07D261/18 ,  C07D277/36 ,  C07D277/56 ,  C07D277/82 ,  C07D295/15 ,  C07D295/32 ,  C07D307/24 ,  C07D307/68 ,  C07D317/68 ,  C07D333/38 ,  C07D333/68 ,  C07D333/72

Abstract: Compounds having the formula are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.

Abstract translation: 具有下式的化合物是甲硫氨酸氨基肽酶2（MetAP2）抑制剂，可用于抑制血管发生。 还公开了抑制哺乳动物血管生成的MetAP2抑制组合物和方法。

公开(公告)号：EP1846362A2

公开(公告)日：2007-10-24

申请号：EP06717579.4

申请日：2006-01-05

Applicant: ABBOTT LABORATORIES

Inventor： ROHDE, Jeffrey, J. ,  SHUAI, Qi ,  LINK, James, T. ,  PATEL, Jyoti, R. ,  DINGES, Jurgen ,  SORENSEN, Bryan, K. ,  YONG, Hong ,  KURUKULASURIYA, Ravi ,  YEH, Vince

IPC: C07C233/63 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24 ,  A61K31/165 ,  A61K31/4409 ,  A61K31/381 ,  A61K31/415 ,  A61K31/42 ,  A61P3/04 ,  A61P3/10

CPC classification number: C07D207/277 ,  C07C233/11 ,  C07C233/52 ,  C07C233/58 ,  C07C233/63 ,  C07C237/24 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/74 ,  C07D211/78 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶的抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。

公开(公告)号：EP1363876A1

公开(公告)日：2003-11-26

申请号：EP02714910.3

申请日：2002-02-12

Applicant: Abbott Laboratories

Inventor： LINK, James, T. ,  SORENSEN, Bryan, K. ,  PATEL, Jyoti, R. ,  ARENDSEN, David, L. ,  LI, Gaoquan

IPC: C07C307/04 ,  C07C311/08 ,  A61K31/18 ,  A61P3/10

CPC classification number: C07D295/088 ,  C07C307/10 ,  C07C311/08 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/18

Abstract: Compounds of formula (I) (I), or pharmaceutically acceptable salts thereof are novel glucocorticoid receptor modulators and are useful for treating type II diabetes in a mammal.

Abstract translation: 式（I）（I）化合物或其药学上可接受的盐是新型糖皮质激素受体调节剂，可用于治疗哺乳动物的II型糖尿病。